We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a series of high-profile departures involving senior R&D figures at top drugmakers.

Jacquie Ross, Vice President, Investor Relations at Gilead Sciences Thank you, Rebecca ... the market is primarily white MSMs ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily ... that results in lower-than-normal levels of a type of white ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the ...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers ...

Gilead’s HIV sector, populated by dominant HIV treatment Biktarvy and PrEP Descovy, contributed $5.1 billion to the company’s total quarterly sales haul of $7.5 billion, reflecting growth of 7 ...

November 06, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the ...